Femme Homme
- | Pays :
- Pakistan
- | Organes : -
- | Spécialités : -
Extrait
This observational study will evaluate the routine clinical use and the safety and efficacy of capecitabine (Xeloda®) in participants with metastatic or advanced breast cancer. Eligible participants will be followed for up to 24 months.
Critère d'inclusion
- Breast Cancer